Dey
21
0
0
21
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
0.0%
0 terminated/withdrawn out of 21 trials
100.0%
+13.5% vs industry average
33%
7 trials in Phase 3/4
5%
1 of 21 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (21)
Study to Evaluate the Safety of Long-Term Use of Perforomist® (Formoterol Fumarate)
Role: lead
A 12-Week Study in Adult Subjects With Asthma
Role: lead
12-Week Study in Adult Subjects With Asthma
Role: lead
Pilot Study to Determine Efficacy of Cyclamen Europaeum Extract Nasal Spray in Patients With Acute Sinusitis
Role: lead
A Trial to Assess the Pharmacodynamic Response in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Role: lead
A Study Characterizing Pharmacodynamic Profiles in Subjects With Chronic Obstructive Pulmonary Disease
Role: lead
A Study Evaluating Systemic Exposure and Pharmacodynamics in Patients With Chronic Obstructive Pulmonary Disease
Role: lead
Study in Subjects Greater Than 40 Years of Age With COPD
Role: lead
A Trial to Evaluate the Efficacy and Safety of Formoterol Fumarate 20 Mcg/0.5 mL in the Treatment of Patients With COPD
Role: lead
Study in Patients With COPD
Role: lead
Study in Patients With Asthma
Role: lead
Study in Patients With COPD
Role: lead
Study in Patients With Asthma
Role: lead
Study in Patients With Asthma
Role: lead
Study in Patients With COPD
Role: lead
Study in Patients With Asthma
Role: lead
A Trial to Evaluate the Efficacy and Safety of Formoterol Fumarate in the Treatment of Patients With COPD
Role: lead
A Dose-Finding Study Evaluating Safety and Efficacy in Patients With Chronic Obstructive Pulmonary Disease
Role: lead
A Crossover Study in the Treatment of Patients With COPD
Role: lead
A Study in Healthy Volunteers to Evaluate Serum and Urine Levels of the Investigational Product Versus Comparator.
Role: lead